Recombinant lactic acid bacteria as mucosal biotherapeutic agents

被引：76

作者：

Daniel, Catherine ^{[1
]}

Roussel, Yvonne ^{[2
]}

Kleerebezem, Michiel ^{[3
,4
]}

Pot, Bruno ^{[1
]}

机构：

[1] Univ Lille Nord France, CNRS, Inst Pasteur Lille,UMR 8204,U1019, Ctr Infect & Immun Lille,Inst Natl St & Rech Med, F-59019 Lille, France

[2] Nancy Univ, Unite Rech Anim & Fonctionnalites Prod Anim, Equipe Proteolyse Biofonctionnalite Prot & Peptid, Fac Sci & Tech,UHP, F-54506 Vandoeuvre Les Nancy, France

[3] NIZO Food Res, Dept Hlth, NL-6710 BA Ede, Netherlands

[4] Wageningen Univ, Microbiol Lab, NL-6703 HB Wageningen, Netherlands

来源：

TRENDS IN BIOTECHNOLOGY | 2011年 / 29卷 / 10期

关键词：

LACTOBACILLUS-PLANTARUM GENES; MODIFIED LACTOCOCCUS-LACTIS; IN-VIVO; IMMUNOMODULATORY PROPERTIES; LISTERIA-MONOCYTOGENES; PROTECTIVE ANTIGEN; IMMUNE-RESPONSES; EPITHELIAL-CELLS; VACCINE DELIVERY; LETHAL CHALLENGE;

D O I：

10.1016/j.tibtech.2011.05.002

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health.

引用

页码：499 / 508

页数：10

共 50 条

[31] LAB (lactic acid bacteria) as live vectors for the development of safe mucosal vaccines
Wyszynska, Agnieszka
Kobierecka, Patrycja
Jagusztyn-Krynicka, Elzbieta Katarzyna
[J]. POSTEPY MIKROBIOLOGII, 2015, 54 (02): : 141 - 153
[32] Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria
Grangette, C
Müller-Alouf, H
Hols, P
Goudercourt, D
Delcour, J
Turneer, M
Mercenier, A
[J]. INFECTION AND IMMUNITY, 2004, 72 (05) : 2731 - 2737
[33] Saccharomyces cerevisiae and lactic acid bacteria as potential mycotoxin decontaminating agents
Shetty, PH
Jespersen, L
[J]. TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2006, 17 (02) : 48 - 55
[34] Lactic Acid Bacteria as Potential Agents for Biocontrol of Aflatoxigenic and Ochratoxigenic Fungi
Maria Mateo, Eva
Tarazona, Andrea
Jimenez, Misericordia
Mateo, Fernando
[J]. TOXINS, 2022, 14 (11)
[35] THE BIOANALYTICAL METHODS TO CHARACTERIZE ANTIFUNGAL AGENTS PRODUCED BY LACTIC ACID BACTERIA
Lipinska, Lidia
Klewicka, Elzbieta
[J]. CECE 2014: 11TH INTERNATIONAL INTERDISCIPLINARY MEETING ON BIOANALYSIS, 2014, : 313 - 315
[36] Sourdough lactic acid bacteria as antifungal and mycotoxin-controlling agents
Hassan, Yousef I.
Zhou, Ting
Bullerman, Lloyd B.
[J]. FOOD SCIENCE AND TECHNOLOGY INTERNATIONAL, 2016, 22 (01) : 79 - 90
[37] The lactic dehydrogenase of lactic acid bacteria
Katagiri, H
Kitahara, K
[J]. BIOCHEMICAL JOURNAL, 1938, 32 : 1654 - 1657
[38] Lactic acid bacteria
Bangar S.P.
Sharma N.
Bhardwaj A.
Phimolsiripol Y.
[J]. Quality Assurance and Safety of Crops and Foods, 2022, 14 (02): : 13 - 31
[39] Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
de Moreno de LeBlanc, Alejandra
del Carmen, Silvina
Chatel, Jean-Marc
Azevedo, Vasco
Langella, Philippe
Bermudez-Humaran, Luis
Guy LeBlanc, Jean
[J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2016, 65 : 1038 - 1046
[40] Recombinant lactic acid bacteria as delivery vectors of heterologous antigens: the future of vaccination?
Trombert, A.
[J]. BENEFICIAL MICROBES, 2015, 6 (03) : 313 - 324

← 1 2 3 4 5 →